Current viral-mediated gene transfer research for treatment of Alzheimer’s disease

  title={Current viral-mediated gene transfer research for treatment of Alzheimer’s disease},
  author={Andrew Octavian Sasmita},
  journal={Biotechnology and Genetic Engineering Reviews},
  pages={26 - 45}
  • A. O. Sasmita
  • Published 14 October 2018
  • Biology
  • Biotechnology and Genetic Engineering Reviews
ABSTRACT Alzheimer’s disease (AD) is the most common form of dementia and has affected millions of individuals worldwide. The hallmarks of AD include the amyloid beta plaque deposits, tau neurofibrillary tangles, altered neuronal signaling, alongside decline in memory and cognitive functions. Conventional drug therapies do exist, such as donepezil or aducanumab, but these drugs mostly focus on halting AD progression instead of causing a reversal within the disease. In an effort to ameliorate… 
Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review
Infusion of aducanumab at a higher dose resulted in a modest slowing of cognitive decline among patients with mild cognitive impairment or early-onset AD dementia, making it the first disease-modifying therapy approved for the treatment of AD.
Characteristics and advantages of adeno-associated virus vector-mediated gene therapy for neurodegenerative diseases
Adeno-associated virus has been the vector of choice in recent clinical trials of therapies for neurodegenerative diseases due to its safety and efficiency in mediating gene transfer to the central nervous system.
Nanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimer's disease.
Modification of the gut microbiome to combat neurodegeneration
Present studies and clinical trials indicate that although there is an immense potential of gut microbiome modification to be preventive or therapeutic, there are still many intercalated components of the gut-brain axis at play and thus, more research needs to be carried out to delineate microbiome factors that may potentially alleviate symptoms of neurodegeneration.
Principles of Neurochemistry: Fundamentals and Applications
This chapter is intended to serve as a brief introduction to neurotransmission and the many types of neurotransmitters.


Immunotherapy for Alzheimer’s disease: hoops and hurdles
  • C. Lemere
  • Biology
    Molecular Neurodegeneration
  • 2013
Efforts are now underway to treat individuals at risk for AD prior to or in the earliest stages of cognitive decline with the hope of preventing or delaying the onset of the disease.
Gene Therapy in Alzheimer Disease-It May Be Feasible, but Will It Be Beneficial?
This trial was to treat the cholinergic deficit in AD, using a viral vector to deliver DNA that codes for nerve growth factor into the brain’s nucleus basalis of Meynert (NBM) through stereotactic neurosurgery, and did not show evidence of benefit.
Viral gene transfer of APPsα rescues synaptic failure in an Alzheimer’s disease mouse model
Sustained APPsα overexpression in aged mice with already preexisting pathology and amyloidosis restored synaptic plasticity and partially rescued spine density deficits, and AAV-APPsα treatment resulted in a functional rescue of spatial reference memory in the Morris water maze.
Neuroinflammation in the pathogenesis of Alzheimer’s disease. A rational framework for the search of novel therapeutic approaches
The role of microglial and astrocytic cells, the principal agents in neuroinflammation process, in the development of neurodegenerative diseases such as AD are discussed and the potential relevance of natural anti-inflammatory components, which include curcumin and the novel Andean Compound, are evaluated.
CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease.
  • R. Mandel
  • Biology
    Current opinion in molecular therapeutics
  • 2010
CERE-110 (AAV2-NGF), under development by Ceregene Inc, is an AAV serotype 2-based vector expressing human NGF delivered to the nucleus basalis of Meynert by stereotactic injection for the treatment of AD.
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner, accompanied by a slowing of clinical decline measured by Clinical Dementia Rating—Sum of Boxes and Mini Mental State Examination scores.
Nerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease.
Findings indicate that neurons of the degenerating brain retain the ability to respond to growth factors with axonal sprouting, cell hypertrophy, and activation of functional markers, and growth factor therapy appears safe over extended periods and merits continued testing as a means of treating neurodegenerative disorders.
Lentivirus-expressed siRNA vectors against Alzheimer disease.
It is demonstrated that decreasing the expression of Bace1 via lentiviral vector delivery of BACE1 siRNA has the potential for significantly reducing the cleavage of APP, accumulation of these products, and consequent neurodegeneration.
Natural compounds that modulate BACE1-processing of amyloid-beta precursor protein in Alzheimer's disease.
The background of AD and the biological aspects of BACE1 are discussed, and the effects of several natural products that modulate Bace1-processing of APP are discussed.
An overview on therapeutics attenuating amyloid β level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels.
Alzheimer's disease (AD) is the most common underlying cause of dementia, and novel drugs for its treatment are needed. Of the different theories explaining the development and progression of AD,